

URGENT: FIELD SAFETY NOTICE

Philips Respironics

Trilogy 100, Trilogy 200, Garbin Plus, Aeris, LifeVent, BiPAP V30, and BiPAP A30/A40 Series Device Models

Sound Abatement Foam Susceptibility to Degradation and Volatile Organic Compound Emission

Dear Device Customer,

Philips Respironics is issuing a Field Safety Notification about the below devices due to two (2) issues related to the polyester-based polyurethane (PE-PUR) sound abatement foam used in Philips Continuous and Non-Continuous Ventilators: 1) PE-PUR foam may degrade into particles which may enter the device's air pathway and be ingested or inhaled by the user, and 2) the PE-PUR foam may emit certain chemicals. The foam degradation may be exacerbated by use of unapproved cleaning methods, such as ozone (see [FDA safety communication](#) on use of Ozone cleaners). Emission of chemicals may occur during operation.

These issues can result in serious injury which can be life-threatening, cause permanent impairment, and/or require medical intervention to preclude permanent impairment. To date, Philips Respironics has received several complaints regarding the presence of black debris/particles within the airpath circuit (extending from the device outlet, humidifier, tubing, and mask). Philips also has received reports of headache, upper airway irritation, cough, chest pressure and sinus infection. The potential risks of particulate exposure include: Irritation (skin, eye, and respiratory tract), inflammatory response, headache, asthma, adverse effects to other organs (e.g. kidneys and liver) and toxic carcinogenic effects. The potential risks of chemical exposure due to emission of chemicals include: headache/dizziness, irritation (eyes, nose, respiratory tract, skin), hypersensitivity, nausea/vomiting, toxic and carcinogenic effects. There have been no reports of death as a result of these issues.

All Devices manufactured before 26 April 2021, All serial numbers

Continuous Ventilator	Trilogy 100
	Trilogy 200
	Garbin Plus, Aeris, LifeVent
Continuous Ventilator, Minimum Ventilatory Support, Facility Use	A-Series BiPAP Hybrid A30 (not marketed in US)
	A-Series BiPAP V30 Auto
Continuous Ventilator, Non-life Supporting	A-Series BiPAP A40
	A-Series BiPAP A30

Immediate Actions to be taken by You, the User:

1. Do not stop or alter your prescribed therapy until you have talked to your physician. Philips recognizes that alternate ventilator options for therapy may not exist or may be severely limited for patients who require a ventilator for life-sustaining therapy, or in cases where therapy disruption is unacceptable. In these situations, and at the discretion of the treating clinical team, the benefit of continued usage of these ventilator devices may outweigh the risks.
2. If your physician determines that you must continue using this device, **use an inline bacterial filter**. Consult your Instructions for Use for guidance on installation.
3. Register your device(s) on the field action website **<to be completed on a country basis>**
 - a. The website provides you current information on the status of the field action and how to receive permanent corrective action to address the two (2) issues.
 - b. The website also provides you instructions on how to locate your device Serial Number and will guide you through the registration process.
 - c. Call **<to be completed on a country basis>** if you cannot visit the website or do not have internet access.

Permanent Corrective Action to be Taken by the Company:

Philips is deploying a permanent corrective action to address the two (2) issues described in this Field Safety Notification. As part of the registration process above, you will be provided information on the next steps to implement the permanent solution.

Other Information:

If you need any further information or support concerning this issue, please contact the support hotline or visit the website:

[Insert 1-800 TOLL free line] <to be completed on a country basis>

<to be completed on a country basis>

This notice has been reported to the appropriate Regulatory Agencies.

Philips regrets any inconveniences caused by this problem.

Sincerely,

Rodney Mell
Head of Quality and Regulatory
Philips Respironics - Sleep & Respiratory Care